Drug Royalty Investment Companies as Catalysts for Innovation

Drug royalty investment companies have channeled billions of dollars into the biopharma industry that would otherwise have been invested elsewhere. However, targeted therapies and personalized medicine are changing the economic terms of such funds, and new business models are needed to address these changes, which will be described in this talk.